Wearables for the Bladder: Stakeholder Perspectives on Moving Multiple Sclerosis Bladder Dysfunction Interventions Into the 21st Century.

Autor:	Block VJ; From the Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA.; Department of Physical Therapy and Rehabilitation Science, University of California San Francisco, San Francisco, CA., McIntyre Née Wylie L; Department of Physical Therapy and Rehabilitation Science, University of California San Francisco, San Francisco, CA., Sisodia N; From the Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA., Van Kuiken ME; Department of Urology, University of California San Francisco, San Francisco, CA., Suskind AM; Department of Urology, University of California San Francisco, San Francisco, CA., Bove R; From the Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA.
Jazyk:	angličtina
Zdroj:	International journal of MS care [Int J MS Care] 2024 Oct 21; Vol. 26 (Q4), pp. 290-301. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024).
DOI:	10.7224/1537-2073.2023-108
Abstrakt:	Background: Bladder dysfunction (BD) is common in people with multiple sclerosis (MS) and can reduce participation in daily life. Detecting BD early allows for effective prevention-focused treatments such as pelvic floor physical therapy. Pairing neurotechnology with patient-reported outcomes to remotely measure BD could significantly improve monitoring and treatment of BD. Therefore, we describe the process and findings of stakeholder engagement from a human-centered design process to assemble a wearables for the bladder (WeB) kit. Methods: Four people with MS with varying BD severity, and 5 MS clinical/research experts had 4 virtual meetings. Commercially available bladder tools were graded for ability to evaluate, monitor, or treat BD. The Health Information Technology Usability Evaluation Scale (utility, usability, feasibility) was used for evaluation. Scoring was performed individually and as a group. Results: Of the 11 devices, 5 obtained mean scores of greater than 6 of 10 for likability, usability, and device utility. The 2 highest scoring (9/10) devices were selected for the pilot. One device measures bladder urine levels, reporting the number/frequency of voids/leaks; the other guides pelvic floor exercises by pairing games on an app with biofeedback from intravaginal sensors. We uncovered critical differences in experts' and patients' appreciation of the tools, and the collaborative engagement led to substantial revisions of initial tool scores. Conclusions: This process underscores the critical role of stakeholder engagement in the selection of digital tools, especially in sensitive domains like pelvic function. Ongoing clinical validation of the selected tools will yield a validated, user-friendly WeB kit that is able to fill gaps in our ability to evaluate BD treatments in people with MS, ultimately reducing the impact of BD on quality of life. (© 2024 Consortium of Multiple Sclerosis Centers.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu